{"name":"Aurobac Therapeutics SAS","slug":"aurobac-therapeutics-sas","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ATX101","genericName":"ATX101","slug":"atx101","indication":"Atrial fibrillation for stroke prevention","status":"phase_2"}]}],"pipeline":[{"name":"ATX101","genericName":"ATX101","slug":"atx101","phase":"phase_2","mechanism":"ATX101 is a small molecule that acts as a selective inhibitor of the sodium-activated potassium channel, Nav1.5.","indications":["Atrial fibrillation for stroke prevention"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxQMzlWWEJhTkVURXg3QzJjZFdKRWlhbnJRRDNnekQtUC1SLTIzS2ZQNTJDWVcyQnUwLUhHTEVXblg1eXlkMnVZZzdRYng3Qm1LeG9CX3RYdkJwV3B0VXE3U3BWZWV0cUIyODJ2RHd2ZHI4VWJCYUt1ZU45VEpDVVVYSUx1a21VekhPNjM4Wm4tZ1hscHh5U0FXX1JHbFVvZk9wdEFCQkI2RzVfVjRJcFkxUC1NR0NzREpwMVdDRlJTRzhfX3VyMlZhaWJJaXFmb1ZJWEE?oc=5","date":"2024-06-04","type":"pipeline","source":"BioWorld News","summary":"Aurobac Therapeutics outlines plans to target bacterial infections and antimicrobial resistance - BioWorld News","headline":"Aurobac Therapeutics outlines plans to target bacterial infections and antimicrobial resistance","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxQQVJmRUhVeFE0U2labmZfSVlUY1ZaekYxVnBuc1RrSkVDVFdJSzVvZFItUkdZanRBUllHR2ZBV08teFlTVlZYZUhabGJIa3NrVGVVTFNvVlZ1bUxBcFo4VjB5UV9MYXhHblpvcm5oeV9lUDNlNEFJQUQ1amtFb1pteFdZajI1UHpiNHBfQUgzajQ?oc=5","date":"2022-11-04","type":"pipeline","source":"European Biotechnology Magazine","summary":"AMR joint venture Aurobac appoints CEO - European Biotechnology Magazine","headline":"AMR joint venture Aurobac appoints CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNeDBWSDJiRXZzUG9aVmtWcU5iem9sZVFWYmVmelNzZWVHbTB1RXdfYUtBU0JKQ1N2TkRDM0hTMlE4YVVqLUtPeEExYU9wY210MkFMczlkakVqbmUtRlhEUU1sMWxYajg0dzZGUUZMMTRhXzBQQ1k0TTJSNTlBMUJNa3NWelF0MWUtM2RfM3ZHY0RoLXl0QW9veHFUSW03S0pkUHRzVVJqT3RVeGJLa3paanRKeGNDamFOR1V1eUxB?oc=5","date":"2022-07-11","type":"pipeline","source":"European Pharmaceutical Review","summary":"Aurobac Therapeutics launched to fight antimicrobial resistance - European Pharmaceutical Review","headline":"Aurobac Therapeutics launched to fight antimicrobial resistance","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxOZ3d1Zm4weENRYmt4a3FKcWc1ZUJiOVdNRjN2cDRVZ0N5NnRLZHFZaUNPVlphRk90WGNUOEwwVHdfN2thNUFlUVBiaUU4akdUVjhXVkJqeXVFNDY3ZFFBdHk0U2R4d0hsNGsySjlkMWUxdUlXeUZlY2RqNW9mMnBJbUlvZGlURXdPcFY4eG9qQkFjRkdNeEVqeUZlN2d0NVNYUzhUTTNOTzFrc21CRS0yajdyRU8yak81alpWX2M2UnRJdw?oc=5","date":"2022-07-06","type":"pipeline","source":"Boehringer Ingelheim","summary":"Joint venture to fight Antimicrobial Resistance - Boehringer Ingelheim","headline":"Joint venture to fight Antimicrobial Resistance","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}